Sovilnesib

Cat. No.:	HY-132840
CAS No.:	2410796-79-9
Molecular Formula:	$C_{26}H_{34}F_2N_6O_4S$
Molecular Weight:	564.65
Target:	Microtubule/Tubulin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (177.10 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.7710 mL	8.8550 mL	17.7101 mL
	5 mM	0.3542 mL	1.7710 mL	3.5420 mL
	10 mM	0.1771 mL	0.8855 mL	1.7710 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (4.43 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC_{50} value of 0.071 μM. Sovilnesib can be used for the research of cancer[1][2].

IC_{50} & Target

KIF18A[1]

In Vitro

Sovilnesib (AMG 650; 0-10 pM; 96 and 144 h; cancer cell lines) has anti-proliferative activity and inhibits tumor cell growth in a dose-dependent manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	Cancer cell lines
Concentration:	0-10 pM
Incubation Time:	96 and 144 hours
Result:	Inhibited tumor cell growth in a dose-dependent manner.

In Vivo

Sovilnesib (AMG 650; 10-100 mg/kg; p.o. daily, for 45 d; female nude mice without thymus with OVCAR-3 xenografts) inhibits tumor growth, Lasting tumor regression and cure occurred in 50% of the animals, Sovilnesib has no apparent toxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice without thymus with OVCAR-3 xenografts
Dosage:	10, 30, and 100 mg/kg
Administration:	Oral administration; daily, for 45 days
Result:	Had antitumor efficacy in a dose-dependent manner.

REFERENCES

[1]. Payton MN, et, al. Kif18a inhibitors for treatment of neoplastic diseases. WO2021211549

[2]. Tamayo NA, et, al. Kif18a inhibitors. WO2020132648.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA